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The virulence ofmany pathogenic viruses depends on suppression of the innate type I interferon defense. For
influenza viruses, a unique strategy has nowbeen unraveled, as the viral nonstructural protein 1was shown to
inhibit activation of the pathogen recognition receptor RIG-I by binding the ubiquitin ligase TRIM25.Induction of type I interferon (IFN) confers
an antiviral state to cells and limits the
replication and spread of viral pathogens,
including human and swine influenza
viruses (Garcia-Sastre and Biron, 2006).
Many different cell types are capable of
producing type I IFN, allowing them to
respond immediately to an invading virus
andprepareneighboringcells for the immi-
nent pathogen attack. Secreted IFN-a and
IFN-b bind to a common IFN-a/-b receptor
(IFNAR), which, by signaling through the
JAK-STATpathway, leads to theactivation
of the trimeric transcription factor ISGF3
that in turn induces a multitude of latent
host genes. Many of those IFN-induced
gene products, such as the Mx protein or
p56, have strong antiviral activities by
themselves. Others, like the 20-50-oligoa-
denylate synthetases (OAS) and the
protein kinase PKR, require the additional
cofactor dsRNA for activation after virus
infection. In addition, type I IFNs also
activate various immune cells, such as
dendritic cells, and therefore have addi-
tional importance for the initiation of
adaptive immune responses (Fernandez-
Sesma, 2007; Garcia-Sastre and Biron,
2006).
For decades, it was believed that long
dsRNAs formed during viral replication
were responsible for type I IFN induction,
as this reaction could be mimicked by
transfectionof syntheticdsRNA.However,
the specific receptor proteins for viral
nucleic acids leading to IFN induction re-
mained unknown, and there was also little
experimental evidence for the production
of dsRNA in cells infected with some
groups of viruses, including influenza
viruses.
However, our understanding of these
processes was substantially advanced420 Cell Host & Microbe 5, May 21, 2009 ª2since the recent identification of a
receptor-signaling system that is essential
for antiviral responses to RNA viruses
(Figure 1). It became evident that the RNA
helicases MDA5 and RIG-I are intra-
cellular receptors for dsRNAand/or single-
stranded RNAs carrying 50-triphosphate
groups. Engagement of these receptors
triggers a signaling module that leads, via
interaction with the mitochondrial IFN-b
promoter stimulator 1 protein (IPS-1, also
known as MAVS/VISA/Cardif), to the acti-
vation of type I IFN genes by transcription
factors, most importantly the IFN regula-
tory factors IRF-3 and IRF-7. These factors
are activated through phosphorylation by
the Ik-B kinase family members TBK-1 or
IKK-3 (reviewed by Wolff et al., 2008).
Just recently, the picture was completed
by the finding that interaction of RIG-I
with its downstream effectors requires
polyubiquitination within its second cas-
pase recruitment domain (CARD), induced
by the tripartite motif protein 25 (TRIM25),
an E3 ubiquitin ligase (Gack et al., 2007)
(Figure 1).
Given this powerful antiviral defense
signaling program, it is no surprise that
during coevolution with their hosts, prob-
ably all natural viruses have evolved gene
products that interfere with the IFN-a/-b
system at the induction or effector level
(Garcia-Sastre and Biron, 2006). Influenza
virus was the virus of choice that led to the
discovery of IFN more than 50 years ago
by Isaacs and Lindenmann (Isaacs and
Lindenmann, 1957). Studies with this virus
also provided the first indications of viral
IFN counteraction. While Isaacs and
Lindenmann observed induction of an
‘‘interfering’’ activity with heat-inactivated
influenza virus, this was not seen with the
replication competent strain, providing009 Elsevier Inc.the first evidence that live influenza virus
actually produces suppressive factors.
However, it took many years in virus
research before it was realized that the
viral nonstructural protein 1 (NS1) is the
main weapon of influenza virus to antago-
nize IFN expression, both at the level of
induction andmRNAprocessing (Figure 1)
(reviewed by Hale et al., 2008). The para-
mount importance of the NS1 protein for
viral virulence was first illustrated by the
apathogenic phenotype of an engineered
NS1-deletion virus in wild-type hosts,
which retained virulence in STAT1/
mice (Garcia-Sastre et al., 1998). In the
following years, it was well established
by several laboratories that the NS1
proteins of both influenza A and B viruses
antagonize antiviral signaling events initi-
ated by the RIG-I helicase, themajor path-
ogen recognition receptor for influenza
viruses (Kato et al., 2006). However, the
exact mode of action remained unclear.
It was widely believed that the dsRNA-
binding NS1 proteins inhibit antiviral reac-
tions by sequestration of suspected
dsRNA produced during viral replication.
However, little dsRNA was detected in
influenza virus-infected cells, and muta-
tional inactivation of the dsRNA binding
domain of the NS1 protein only partially
eliminated IFN inhibition (reviewed inWolff
et al., 2008).
This puzzle has now been resolved by
the work of Gack and colleagues, pre-
sented in this issue ofCell Host &Microbe.
The human TRIM25 protein was identified
as a crucial binding target of the NS1
protein (Figure 1). The NS1-TRIM25 inter-
action inhibits ubiquitination of RIG-I and
further downstream antiviral signaling
events, including binding to IPS-1 (Gack
et al., 2009). The mutational perturbation
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PreviewsFigure 1. Influenza A Virus Inhibits the RIG-I Signaling Module by Binding of the Viral NS1
Protein to TRIM25
The viral genome is replicated in the nucleus of the infected cell. Late in infection, the viral gene segments
carrying a 50-triphosphate group are exported to the cytoplasm, where they are recognized by the RNA
helicase RIG-I, inducing a conformational change. Subsequently, RIG-I binds to the mitochondrial
IPS-1, which requires ubiquitination of RIG-I in the secondCARDby the ubiquitin ligase TRIM25. This inter-
action triggers subsequent signaling for the activation of the transcription factors IRF-3/-7 that induce type
I IFN genes. As shown by Gack et al., 2009, the viral NS1 protein forms a complex with TRIM25, which was
shown to reduce ubiquitination of RIG-I and its downstream signaling for IFN induction. NS1 proteins of
some influenza A viruses also inhibit the export of cellular poly(A)-RNA to the cytoplasm, including
transcripts of antiviral genes.ofNS1binding toTRIM25 ina recombinant
influenza A virus led to a strong increase in
IFN induction in vitro andconcomitant loss
of virulence in vivo. Remarkably, NS1
proteins from human, avian, and porcine
influenza viruses interacted with TRIM25,
indicating that the suppressive activity on
RIG-I signaling is conserved in influenza
A virus strains of different host back-
grounds. This mechanism of action of the
NS1 protein is a mode of IFN suppression
that has not been observed for other
viruses before.
While this is an important step to
improve our understanding of how the
NS1manipulates the cell for efficient repli-
cation, the complete picture of NS1 action
has yet to be unveiled. Different recent
studies have identified a variety of other
cellular interaction partners of NS1
besides TRIM25, including PKR, PI3K,
CrkI/CrkL, CPSF, and many others (Haleet al., 2008). It has yet to be determined
when and where binding of NS1 to these
proteins occurs and to what extent the
interaction with the different proteins
contributes to efficient viral replication.
Knowledge of IFN suppressive mecha-
nisms of the influenza virus NS1 protein is
notonly interesting fromanacademicpoint
of view but is also important with regard to
translation into practical approaches for
the control of these dangerous pathogens.
To this end, novel concepts for live attenu-
ated vaccines based on NS1-engineered
influenza virus have been successfully
explored in animal models and were found
promising for further clinical development
(reviewed in Hale et al., 2008). In addition,
a recent study suggested that the NS1
protein might be amenable to a novel anti-
viral concept that strengthens the innate
antiviral defense. Screenings of a small
molecule library led to the identification ofCell Host & Microbthree compounds that were able to inhibit
NS1 activities in the suppression of IFN
induction and reduced viral propagation
(Basu et al., 2009). The recent appearance
of the novel influenza A (H1N1) reassortant
virus in the Mexican population and its
unprecedented rapid worldwide spread
highlight that such innovative antiviral
approaches are highly needed for
strengthening our arsenal against these
malicious pathogens.
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